Abstract
A 28-year-old woman with known relapsing-remitting multiple sclerosis (RRMS) for 2 years was seen in the emergency room for a subacute onset of right-hemibody paresthesia and weakness. Her symptoms had started 3 days prior and were gradually worsening. She was taking an injectable disease-modifying therapy (DMT), glatiramer acetate, that was well tolerated. Her most recent brain MRI was a year ago and her lesion load was stable. She was otherwise in good general health and did not have any infectious symptoms or fever in the weeks preceding her clinical presentation. She had no systemic symptoms and had never experienced these symptoms before.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. New Engl J Med. 2000;343:938-952.
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 269:292-302.
Hirst CL, Ingram G, Pickersgill TP, et al. Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome. Mult Scler. 2012;18:1152-1158.
Iuliano G, Napoletano R, Esposito A. Multiple sclerosis: relapses and timing of remissions. Eur Neurol. 2008;59:44-48.
Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61:1528-1532.
Mowry EM, Pesic M, Grimes B, et al. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology. 2009;72:602-608.
Vercellino M, Romagnolo A, Mattioda A, et al. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurol Scand. 2009;119:126-130.
Leone MA, Bonissoni S, Collimedaglia L, et al. Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study. Mult Scler. 2008;14:485-493.
Confavreux C, Vukusic S. The natural history of multiple sclerosis. Revue du Practicien. 2006;56:1313-1320.
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50:121-127.
D’hooghe MB, Nagels G, Bissay V, De Keyser J. Modifiable factors influencing relapses and disability in multiple sclerosis. Mult Scler. 2010;16:773-785.
Galea I, Heesen C. Relapse in multiple sclerosis. BMJ. 2015;350:h1765.
Andersson P-B, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: a critical review. J Neurol Sci. 1998;160:16-25.
Schweingruber A, Reichardt SD, Reichardt HM. Mechanisms of glucocorticoids in control of neuroinflammation. J Neuroendocrinol. 2011;24:174182.
Burton JM, O’Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev. 2012;12:CD006921.
Le Page E, Veillard D, Laplaud DA, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386:974-981.
Kupersmith MJ, Kaufman D, Paty DW, et al. Megadose corticosteroids in multiple sclerosis. Neurology. 1994;44:1.
Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ. 2006; 332:525.
Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: plasmapheresis in neurologic disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76;294-300.
Elovaara I, Kuusisto H, Wu X, et al. Intravenous immunoglobulins are a therapeutic option in the treatment of multiple sclerosis relapse. Clin Neuropharmacol. 2011;34:84-89.
Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease-modifying therapies in multiple sclerosis: subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169-178.
Citterio A, La Mantia L, Ciucci G, Candelise L, Brusaferri F, Midgard R, Filippini G. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database System Rev. 2000;4:CD001331.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Trudelle, AM. (2017). Management of relapses with corticosteroids. In: Giacomini, P. (eds) Case Studies in Multiple Sclerosis. Adis, Cham. https://doi.org/10.1007/978-3-319-31190-6_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-31190-6_4
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-31188-3
Online ISBN: 978-3-319-31190-6
eBook Packages: MedicineMedicine (R0)